Cartesian Therapeutics Files 8-K
Ticker: RNAC · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing
TL;DR
Cartesian Therapeutics filed an 8-K on 4/22 for an 4/19 event. Details are sparse.
AI Summary
Cartesian Therapeutics, Inc. filed an 8-K on April 22, 2024, reporting an event on April 19, 2024. The filing is under "Other Events" and does not specify any material agreements, asset acquisitions, or executive changes. The company was formerly known as Selecta Biosciences Inc. and is incorporated in Delaware.
Why It Matters
This 8-K filing indicates a routine update or event for Cartesian Therapeutics, Inc., but lacks specific details on its business impact.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with no disclosed material events, indicating no immediate new risks.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- Selecta Biosciences Inc. (company) — Former company name
- April 19, 2024 (date) — Date of earliest event reported
- April 22, 2024 (date) — Filing date
FAQ
What specific event is reported under "Other Events" in this 8-K filing?
The filing does not specify the nature of the event reported under "Other Events" beyond the date it occurred.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 19, 2024.
What is the filing date of this 8-K?
This 8-K filing was made on April 22, 2024.
What was Cartesian Therapeutics, Inc. formerly known as?
Cartesian Therapeutics, Inc. was formerly known as Selecta Biosciences Inc.
In which state is Cartesian Therapeutics, Inc. incorporated?
Cartesian Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-04-22 06:25:14
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
- $1.00 — hat it had regained compliance with the $1.00 per share minimum bid price requirement
Filing Documents
- rnac-20240419.htm (8-K) — 27KB
- 0001453687-24-000072.txt ( ) — 148KB
- rnac-20240419.xsd (EX-101.SCH) — 2KB
- rnac-20240419_lab.xml (EX-101.LAB) — 21KB
- rnac-20240419_pre.xml (EX-101.PRE) — 12KB
- rnac-20240419_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 19, 2024, Cartesian Therapeutics, Inc. (the "Company") announced that it had received a letter (the "Compliance Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Requirement"). On January 17, 2024, the Company had received a deficiency letter from Nasdaq notifying the Company that, for the prior 30 consecutive business days, the bid price for the Company's common stock, par value $0.0001 per share (the "Common Stock"), had failed to meet the Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a period of 180 calendar days, or until July 15, 2024, to regain compliance with the Bid Price Requirement. The Compliance Letter received by the Company on April 19, 2024 noted that (i) the Company's Common Stock had a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days from April 5, 2024 through April 18, 2024, (ii) the Company has regained compliance with the Bid Price Requirement and (iii) Nasdaq considers the matter closed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: April 22, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer